

For the Governing Board of the Innovative Medicines Initiative 2 JU.

Annex I

24th Meeting of the IMI2 Governing Board - extraordinary Agenda

12.12.2018 • 14:00–15:00 Brussels time • **by audio-conference** •



Welcome and Introduction

- 1 Adoption of the Agenda and declarations of interests with regard to agenda

Sole item for decision

- 2 IMI2 JU Annual Work Plan and Budget for 2019, together with a revised Manual for submission, evaluation and grant award: for adoption

Annex II

24th extraordinary meeting of the IMI2 Governing Board held on 12.12.2018 • 14:00–15:00 CET • by audio-conference •

Attendance

EFPIA

[REDACTED]	[REDACTED] UCB	attended
[REDACTED]	[REDACTED] Johnson & Johnson	attended
[REDACTED]	[REDACTED] Novartis	attended
[REDACTED]	[REDACTED] EFPIA	attended
[REDACTED]	[REDACTED] Enyo Pharma SA	apologies

Alternate members

[REDACTED]	[REDACTED] EFPIA	attended
[REDACTED]	[REDACTED] Pfizer IMI Office External R&D Innovation	apologies

European Commission

Wolfgang Bartscher	Deputy Chair of the IMI2 Governing Board Deputy Director-General responsible for Research Programmes within the Directorate-General for Research and Innovation	attended
Andrzej Jan Rys	Director responsible for Health systems, medical products and innovation within the Directorate-General for Health and Food Safety	attended
Carlo Pettinelli	Director responsible for Consumer, Environmental and Health Technologies within the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs	apologies
Irene Norstedt	Acting Director responsible for the Health Directorate within the Directorate-General for Research and Innovation - Head of Unit - Innovative and Personalised Medicine	attended

Alternate members

[REDACTED]	[REDACTED] Directorate-General for Research and Innovation	attended
[REDACTED]	[REDACTED] Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs	attended
[REDACTED]	[REDACTED] the Directorate-General for Health and Food Safety	apologies

Observers		
[REDACTED]	[REDACTED] European Commission, DG RTD, Innovative and Personalised Medicine	apologies
[REDACTED]	[REDACTED] European Commission, DG RTD, Innovative and Personalised Medicine	attended
[REDACTED]	[REDACTED] Scientific Research European Commission, DG RTD, Innovative and Personalised Medicine	attended
[REDACTED]	[REDACTED] European Commission, DG GROW, Biotechnology and Food Supply Chain	apologies
[REDACTED]	[REDACTED] substances of human origin European Commission, DG SANTE, Medical products: quality, safety, innovation	apologies
[REDACTED]	[REDACTED] Johnson and Johnson	apologies
[REDACTED]	UCB [REDACTED]	confirmed
IMI2 JU		
Pierre Meulien	Executive Director	attended
[REDACTED]	[REDACTED]	attended
[REDACTED]	[REDACTED]	attended
[REDACTED]	[REDACTED]	attended

Annex III

Decision¹ taken at the 24th extraordinary meeting of the IMI2 Governing Board held on 12.12.2018

Title of the Decision of the Governing Board	Reference of the Decision
Decision of 12 December 2018 adopting the IMI2 JU Annual Work Plan and Budget for 2019, together with a revised Manual for submission, evaluation and grant award	[IMI2-GB-DEC-2018-32]

¹ To be made public on the basis of Article 9.7 of the Governing Board Rules of Procedure.